| Risk-stratified sequential treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for de-novo post-transplant lymphoproliferative disorder: results of the tidal trial S Chaganti, S Maycock, G McIlroy, WA Iqbal, J Mason, E Kanfer, ... Blood 138, 2492, 2021 | 4 | 2021 |
| Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR … R Dillon, S Maycock, A Jackson, S Fox, S Freeman, C Craddock, ... BMC cancer 22 (1), 1174, 2022 | 3 | 2022 |
| Selenium and Vitamin E for Prevention of Non–Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial RT Bryan, SJ Pirrie, B Abbotts, S Maycock, V During, C Lewis, M Grant, ... JAMA network open 6 (10), e2337494-e2337494, 2023 | 2 | 2023 |
| Ibrutinib and obinutuzumab in CLL: MRD responses sustained for several years with deepest MRD depletion in patients with> 1 year prior ibrutinib exposure AC Rawstron, P Hillmen, S Maycock, N Webster, K Brock, RH Boucher, ... Blood 136, 27-28, 2020 | 2 | 2020 |
| Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04) JR Apps, S Maycock, DW Ellison, T Jaspan, TA Ritzmann, D Macarthur, ... Neuro-oncology advances 4 (1), vdac053, 2022 | 1 | 2022 |
| Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial S Chaganti, S Maycock, G McIlroy, A Jackson, R Bishop, S Johnson, ... Blood, 2024 | | 2024 |
| Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial A Moore, S Maycock, G Leverger, O Smith, A Baruchel, Y Bertrand, ... Blood 142, 730, 2023 | | 2023 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma (Glo-BNHL) E Seaford, S Maycock, S Alexander, A Beishuizen, B Wistinghausen, ... Blood 142, 3097, 2023 | | 2023 |
| A Potential Paradigm for the Robust and Systematic Prioritisation of Assets in Academic-Led, Multi-Industry Collaborative Trials in Rare Populations (Glo-BNHL) E Seaford, N Scobie, L Gore, S Alexander, A Beishuizen, ... Blood 142, 6247, 2023 | | 2023 |
| Selenium and vitamin E to prevent recurrence and progression in patients with non-muscle-invasive bladder cancer: the SELENIB randomized clinical trial: results of the SELENIB … R Bryan, S Pirrie, B Abbotts, S Maycock, V During, C Lewis, M Grant, ... JAMA network open, 2023 | | 2023 |
| STUDY PROTOCOL R Dillon, S Maycock, A Jackson, S Fox, S Freeman, C Craddock, ... | | 2022 |
Graham McIlroyUniversity of BirminghamVerified email at doctors.org.uk
